CM International: Bottom opportunities reappear in the Chinese pharmaceutical industry, recommended Johnson Pharmaceutical (03692.HK), Sinobiological (01801.HK), etc.

According to the Wise Finance APP, CICC International released a research report stating that the MSCI China Healthcare Index has fallen by 11.4% from the beginning of 2026 to date, outperforming the MSCI China Index by 0.2%. The bank believes that the recent correction in the pharmaceutical industry is mainly influenced by factors such as fund, policy, and geopolitics, but the long-term trend of Chinese innovative drugs and medical devices going global remains unchanged. From a policy perspective, the regulation of marketing links will benefit the commercialization of innovative drugs with clinical value, and the policy support for innovative drugs has not changed. Biomedicine has been positioned as a pillar industry, and the industry is showing bottom opportunities again.